Welcome to the October edition of the Pharmalys Newsletter!
Pharmalys continues its dynamic growth!
Since the beginning of 2023, we have expanded our global Pharmalys family, welcoming new colleagues in IT, Clinical Operations, Drug safety, Business Excellence and Quality Management departments. They are based in different parts of the world. We are very happy to work with Cheikh Tidiane Faye, Software Manager, based in Senegal; Ravaka Randriamparany and Zoubeida Ben-Chaabane, Clinical Research Associates, based respectively in Madagascar and Tunisia; Chibunna Nmecha, CRA Manager, UK; N’deye Seck, Clinical Project Manager, France; Darshan Hegde, Medical Safety Officer, India, and Jeanette Young, Regulatory Compliance Manager, South Africa.
All of the new recruits at Pharmalys are highly experienced and skilled professionals, working with the quality standards we request to achieve our vision and mission. We thank them all for their hard work and commitment to Pharmalys projects so far.
Last but not least, we would like to introduce Karim Bagaté, Clinical Operations & Safety Director, who joined us a few months ago.
Karim is a Pharmacologist by training and a highly motivated team player with over 22 years of experience in Clinical Research and Drug development within various industries, from fundamental research; non-clinical and clinical studies (phases 1 to 4). His basic research experience led to several scientific publications: bagate k – Search Results – PubMed (nih.gov).
After completing a PhD and a Post doctorate in France and Germany respectively, he worked for various CROs as a non-clinical and clinical project manager, where he had the full responsibility for deliverables, timelines, resources, and budget oversight.
Following his CRO experience, Karim worked for three biotechnology companies in Switzerland (Skyepharma/Vectura, Polyphor and Sotio respectively) where he held various positions including Associate Director for the management of global clinical trial and global program leader. During his time at Skyepharma/Vectura, Karim highly contributed to several development programs that resulted in the approval of marketing the anti-asthmatic drug “Fluiform.” flutiform 125 microgram/5 microgram per actuation pressurised inhalation, suspension – Patient Information Leaflet (PIL) – (emc) (medicines.org.uk).
The combined CRO and biotechnology involvement has provided him with strong leadership experience in cross-functional management in a multi-cultural environment; to achieve strategy and business objectives. Karim’s Pharmacology background has generated a great understanding of science in several therapeutical areas. His 13 years of experience within biotech companies have strengthened his expertise in all aspects of drug development including preclinical, CMC, regulatory, pharmacovigilance and essential document writing, outsourcing management. His innate calmness makes him a good listener, a strong communicator and productive team leader under stressful conditions.
With extensive experience from across Europe, Karim’s career journey has been nothing short of remarkable. Now, the time has come for him to contribute to the development of clinical research in Africa. Karim sees Pharmalys as a unique opportunity to share the experience he’s accumulated over the years with African researchers. While serving as a platform that enables contribution to the education of younger generations, Pharmalys signifies the inclusion of Africa within the global research community and its pivotal role in running clinical trials to shape the future of healthcare, something Karim regards highly.
Pharmalys Business Excellence Philosophy
Pharmalys Limited is a Contract Research Organisation, first established in London, UK in 2008. We have extensive experience leading the design, execution, and reporting of clinical trial programmes that meet international health authority quality and ethical standards in study sites in Europe.
In 2012, we expanded our services to West Africa with our regional headquarters in Dakar, Senegal to bring high quality research operations to Sub-Saharan Africa. Read more: www.pharmalys.com
In parallel to expanding our geographic footprint, we aim to strengthen our presence in Africa with delivering high-standard quality services by highly qualified personnel, who are both empowered and committed. We target the best practices achieving results and improving performance in all facets of our business with the objective to increase the overall organisational performance, create value for its stakeholders, ensure a consistent business strategy and sustainable growth, and ultimately to reach Business Excellence.
Read more about the Business Excellence model we use at Pharmalys
A professional recognition for Pharmalys Chief Executive Officer, Marieme Ba
Marieme Ba has been selected as a member of the Global Health EDCTP3 Stakeholder’s Group! This is an advisory board of EDCTP3, which is a joint undertaking between the EDCTP Association and the European Union for the 3rd decennial programme of EDCTP. Read more: www.globalhealth-edctp3.eu
EDCTP has been an impactful initiative for decades, it is an honour for Marieme to be part of it, and fantastic news for us all!
An introduction meeting was held in September and will be followed by the first meeting on 7th November in Paris, with all the members.
Meet Pharmalys team at the 11th European and Developing Countries Clinical Trials Partnership (EDCTP) Forum in Paris – booths #4 & #5
Pharmalys is a recurrent sponsor of EDCTP events and this year will be no exception. We will participate in the next EDCTP Forum, on 7-10 November 2023 in Paris, France. Read more: https://www.edctp.org/event/eleventh-edctp-forum/
This year holds significant importance as we have booked two booths, with one dedicated to Pharmalys, and the other to Pharmalys Academy of Clinical research Excellence (PACE). PACE is an international online training curriculum designed for scientific graduates. For a few months we have been rolling out the PACE programme with a pilot cohort of 14 learners. The programme takes place over 9 months, with 3 months of online courses consisting of high standard academic training and real-world practice. Through offering live courses, we ensure learners experience the same level of education they would have in an In-person class by practicing breakout sessions and live interactions between learners, instructors, and mentors. The second part of the training programme is a 6 month internship within an organisation that sponsors, manages or conducts clinical trials to directly put the acquired knowledge of our learners into practice.
Designed to bridge the gap between learning and working, the PACE programme has been developed in collaboration with various stakeholders in the sector, ensuring the curriculum aligns with the industry needs and expectations with the ultimate goal of improving the employability of young professionals.
EDCTP gives us the opportunity to present this innovative programme. For more information on PACE and /or Pharmalys, visit us at booths # 4 and #5, and/or click here
